Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Ann Allergy Asthma Immunol. 2010 Dec;105(6):437–443.e1. doi: 10.1016/j.anai.2010.09.010

Figure 1. Study design.

Figure 1

The generation of OVA specific IgE was assessed after two different sensitization/challenge models. (A) The traditional mouse model that involves two intraperitoneal (i.p.) injections of ovalbumin (OVA) plus alum one week apart, followed by an intranasal (i.n.) challenge with OVA on day 14.14 In this model, OVA specific IgE in the serum is determined one week later by ELISA. (B) To determine if exposure to a non-viral antigen (OVA) during a viral infection leads to IgE production against the non-viral antigen, mice were inoculated with Sendai virus (SeV) or UV-inactivated SeV (UV-SeV). Eight days later, OVA was administered i.n. On day 21 post inoculation (p.i.) OVA specific IgE was determined in the serum using ELISA. (C) To see if this anti-OVA IgE was sufficient to induce allergic airway disease, mice that were treated as in (B) were challenged with OVA i.n. on p.i. days 20, 21, and 22, and airway hyper-reactivity and mucous cell metaplasia assessed the following day.